Current Report Filing (8-k)
April 19 2017 - 4:17PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
April 17, 2017
PROPHASE
LABS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
0-21617
|
|
23-2577138
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
file
number)
|
|
(I.R.S.
Employer
Identification
No.)
|
621
N. Shady Retreat Road, Doylestown, PA, 18901
(Address
of principal executive offices)
(Registrant’s
telephone number, including area code):
(215) 345-0919
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-2)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. 13e-4(c))
|
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
April 17, 2017, ProPhase Labs, Inc. (the “Company”) entered into an Employment Agreement Termination and Release Agreement
(the “New Agreement”) with Robert V. Cuddihy, Jr., the Company’s Chief Operating Officer and Chief Financial
Officer. The New Agreement terminates Mr. Cuddihy’s prior employment agreement with the Company (the “Prior Agreement”),
and sets forth the new terms of Mr. Cuddihy’s employment with the Company. The New Agreement was entered into in view of
the Company’s recent successful sale of its Cold-EEZE
®
brand.
The
terms of the New Agreement provide, among other things, that Mr. Cuddihy will remain employed by the Company on an at-will basis
as the Company’s Chief Financial Officer/Chief Accounting Officer; he will cease services as Chief Operating Officer of
the Company but will become Chief Operating Officer/Contract Manufacturing and will focus on operational responsibility for the
Company’s manufacturing business; he will relinquish his rights under the Prior Agreement, including his rights to separation
payments, in consideration for the Company remitting to him a $675,000 termination payment (the “Termination Payment); he
will receive an annual base salary of $350,000 until July 1, 2017, at which time his annual base salary will be reduced to $250,000.
Mr. Cuddihy will also remain eligible to participate in the Company’s equity incentive compensation plans, annual bonus
plans, and employee benefit plans. He will also be entitled to receive four weeks paid vacation and a $1,250 monthly auto allowance.
All of the arrangements with Mr. Cuddihy have been approved by the compensation committee of the Company’s board of directors.
Pursuant
to the terms of the New Agreement, in the event Mr. Cuddihy’s employment is terminated by the Company without Cause (as
defined in the Agreement), Mr. Cuddihy will be entitled to receive a lump sum cash payment, in an amount equal to three months
of his base salary then in effect, and all other accrued and vested but unpaid compensation through the date his employment is
terminated, within two days of such date; provided, however, that in lieu of the severance payment, the Company, in its sole discretion,
may instead provide Mr. Cuddihy a minimum of three months prior notice of termination.
The
payments described in the New Agreement are subject to Mr. Cuddihy’s execution of a general release of claims in favor of
the Company. In addition, in accordance with applicable law, Mr. Cuddihy is entitled to revoke his acceptance of the New Agreement
within seven days of its execution. If he revokes his acceptance, the New Agreement will be of no further force or effect and
Mr. Cuddihy will not be entitled to the benefits described above. If he does not revoke his acceptance, the New Agreement will
be effective as of the eighth day after signing.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
No.
|
|
Description
|
10.1
|
|
Employment
Agreement Termination and Release Agreement
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ProPhase
Labs, Inc.
|
|
|
|
By:
|
/s/
Ted Karkus
|
|
|
Ted
Karkus
|
|
|
Chairman
of the Board, Chief Executive Officer and Director
|
Date:
April 19, 2017
Exhibits
Index
No.
|
|
Description
|
10.1
|
|
Employment
Agreement Termination and Release Agreement
|
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Apr 2023 to Apr 2024